ENANTA PHARMACEUTICALS, INC Net Income (Loss) Available to Common Stockholders, Diluted
ENANTA PHARMACEUTICALS, INC (ENTA) reported Net Income (Loss) Available to Common Stockholders, Diluted of $78.99 million for the 12-month period ending 2015-09-30, per its 10-K filed 2015-12-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2015-12-11
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for the quarter ending 2014-09-30 was -$5.04M.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for the quarter ending 2014-06-30 was $50.05M.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for the quarter ending 2014-03-31 was -$5.20M.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for the quarter ending 2013-12-31 was -$5.37M, a 240.80% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for fiscal 2015 was $78.99M, a 129.37% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for fiscal 2014 was $34.44M.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for fiscal 2013 was -$6.57M, a 334.02% decline from fiscal 2012.
- ENANTA PHARMACEUTICALS, INC net income (loss) available to common stockholders, diluted for fiscal 2012 was $2.81M, a 14.34% increase from fiscal 2011.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2015-09-30 | $78.99M 10-K · filed 2015-12-11 | |||
| 2014-09-30 | -$5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $45.01M derived: sum of 2 quarters · filed 2015-12-11 | $39.81M derived: sum of 3 quarters · filed 2015-12-11 | $34.44M 10-K · filed 2015-12-11 |
| 2014-06-30 | $50.05M 10-Q · filed 2014-08-12 | $44.85M derived: sum of 2 quarters · filed 2014-08-12 | $39.48M 10-Q · filed 2014-08-12 | $35.04M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | -$5.20M 10-Q · filed 2014-05-12 | -$10.57M 10-Q · filed 2014-05-12 | -$15.02M derived: sum of 3 quarters · filed 2015-12-11 | -$19.15M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-12-31 | -$5.37M 10-Q · filed 2014-02-13 | -$9.81M derived: sum of 2 quarters · filed 2015-12-11 | -$13.95M derived: sum of 3 quarters · filed 2015-12-11 | -$18.94M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-09-30 | -$4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | -$8.58M derived: sum of 2 quarters · filed 2015-12-11 | -$13.57M derived: sum of 3 quarters · filed 2015-12-11 | -$6.57M 10-K · filed 2015-12-11 |
| 2013-06-30 | -$4.14M 10-Q · filed 2014-08-12 | -$9.13M derived: sum of 2 quarters · filed 2014-08-12 | -$2.13M 10-Q · filed 2014-08-12 | -$6.21M derived: sum of 4 quarters · filed 2014-12-11 |
| 2013-03-31 | -$4.99M 10-Q · filed 2014-05-12 | $3.35M 10-Q · filed 2014-05-12 | -$2.08M derived: sum of 3 quarters · filed 2014-12-11 | -$6.91M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-12-31 | $3.81M 10-Q · filed 2014-02-13 | $2.92M derived: sum of 2 quarters · filed 2014-12-11 | -$1.91M derived: sum of 3 quarters · filed 2014-12-11 | $3.59M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-09-30 | -$896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | -$5.73M derived: sum of 2 quarters · filed 2014-12-11 | -$226.00K derived: sum of 3 quarters · filed 2014-12-11 | $2.81M 10-K · filed 2014-12-11 |
| 2012-06-30 | -$4.83M 10-Q · filed 2013-08-12 | $670.00K derived: sum of 2 quarters · filed 2013-08-12 | $3.70M 10-Q · filed 2013-08-12 | |
| 2012-03-31 | $5.50M 10-Q · filed 2013-05-15 | $4.45M 10-Q · filed 2013-05-15 | ||
| 2011-09-30 | $2.46M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |